In order to achieve import substitution, domestic pharmaceutical machinery enterprises are enhancing their competitiveness in many aspects

【Pharmaceutical Network Market Analysis】In recent years, China's pharmaceutical equipment industry has made great progress, in the joint efforts of related enterprises and the majority of engineering and technical personnel, China's pharmaceutical equipment industry in the technical level, product quality, product varieties and other aspects of rapid development, and foreign pharmaceutical equipment enterprises is gradually narrowing the gap at the same time, but also has gradually formed a number of pharmaceutical equipment manufacturers with strong research and development capabilities, independent intellectual property rights, in the high-end market with strong competitiveness, such as Chutian Technology, Dongfulong and so on
。 In order to achieve import substitution, domestic pharmaceutical machinery enterprises are accelerating their competitiveness (Image source: Pharma Network) However, in the context of the continuous improvement of the development of the industry, it should also be noted that there are still some gaps between the domestic pharmaceutical equipment industry and developed countries in some technologies, such as high-end product performance and user recognition
.
Therefore, how to improve the brand influence of domestic pharmaceutical machine products and improve production capacity performance will be a problem
that industry enterprises need to work hard to solve.
In this regard, the industry believes that innovation is productivity, but also the vitality of the industry and enterprises, in order to usher in more opportunities, embark on the road of import substitution, we must continue to strengthen independent innovation, continue to increase investment in research and development, and gradually master core technologies
.
It is understood that in the face of the problem of insufficient competitiveness in technology and production capacity in the high-end field, many pharmaceutical equipment companies have launched active actions
.
For example, recently, Dongfulong issued an announcement that the China Securities Regulatory Commission approved the company's registration application
for issuing shares to specific targets.
The company intends to raise no more than 3.
2 billion yuan, mainly to increase the production capacity of pharmaceutical equipment and replenish working capital
.
It is worth noting that Dongfulong also predicted in the registration draft of the 3.
2 billion yuan fixed increase project that "in the future, more and more domestic pharmaceutical equipment manufacturers will further strengthen independent research and development, cut into the pharmaceutical industry chain in multiple links, and achieve import substitution in all directions and fields"
.
In fact, at present, in addition to Dongfulong, Singapore Malaysia Pharmaceutical is building a pharmaceutical equipment industrialization project
.
After the completion of the project, it will form a whole industrial chain of solid preparation-laboratory, customized, production-type and closed production lines
.
In addition, Chutian Technology also said in an institutional survey on July 19 this year that the company had been laying out import substitution in the high-end market of vaccine products three years ago, and product performance and quality had been able to meet the needs of high-end customers, thus entering the supply chain of the high-end vaccine industry and competing
with imported equipment.
At present, the high-end pharmaceutical equipment track has become the key direction of the head enterprises, and the import substitution process is accelerating, which has gradually begun to appear
in the head performance.
It is reported that Chutian Technology mentioned when it was surveyed by institutions on August 28 that the company achieved good results in the first half of 2022, one of which was high-end import substitution
.
In addition, Canaan Company also said in the Chinese report that some of the company's products have reached the international advanced level, among which the quality and performance of the core products have been improved year by year, similar to foreign advanced products, with the strength of import substitution, and the price is much lower than that of foreign imported equipment, meeting the multiple needs of customers for process accuracy, stable performance and economic cost, and has strong competitiveness
in terms of cost performance 。 In general, compared with the foreign high-end pharmaceutical machine market, the domestic high-end pharmaceutical equipment market still has huge space to be tapped, I believe that with the continuous increase of R&D investment of domestic pharmaceutical machinery enterprises, the strengthening of core technology research, and the continuous support of policies, the import substitution space in the field of domestic pharmaceutical machinery will continue to expand in the future, and related enterprises will also usher in more development opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.